Video

Dr. Crawford on the Drawbacks of PSA Screening

Author(s):

E. David Crawford, MD

E. David Crawford, MD from the University of Colorado Health Sciences Center on the Drawbacks of PSA Screening

Related Videos
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Justin M. Watts, MD
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Related Content
W. Robert Lee, MD, MEd, MS
June 12th 2024

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Daniel P. Petrylak, MD, of Yale School of Medicine
June 10th 2024

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

Stephen J. Freedland, MD
June 5th 2024

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC